Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.

ABSTRACT: The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emphasized the urgency to develop effective therapeutics. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the discovery of such therapeutics. The 3C-like protease (3CL^pro), or main protease (M^pro) of SARS-CoV-2 is a valid drug target as it is a specific viral enzyme and plays an essential role in viral replication. We performed a quantitative high-throughput screening (qHTS) of 10 755 compounds consisting of approved and investigational drugs, and bioactive compounds using a SARS-CoV-2 3CL^pro assay. Twenty-three small molecule inhibitors of SARS-CoV-2 3CL^pro have been identifie

SUBMITTER: Zhu W 

PROVIDER: S-EPMC7507806 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature